Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study

2 years ago

SPARKS, NV / ACCESSWIRE / March 27, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased…

Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals

2 years ago

BOULDER, CO / ACCESSWIRE / March 27, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing…

Theralase(R) Release’s 4Q2023 Interim Financial Statements

2 years ago

TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

2 years ago

Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpointsExpects two more Phase 3…

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

2 years ago

TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical…

Årsregnskab 2023 – Et begivenhedsrigt år for selskabet

2 years ago

2023 var et begivenhedsrigt år for selskabet, hvor den primære fokus i første halvår bestod i at overlevere driften af…

SFWJ/MedCana Announces Significant Progress Across Its Operations, Eyes Global Expansion and Enhanced Profitability

2 years ago

AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- via IBN -- SFWJ, doing business as MedCana, a leading entity in…

UPDATE – Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223

2 years ago

-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study…

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

2 years ago

  The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources…

SeaStar Medical to Restate Financials, Sets Business Update Call for April 17

2 years ago

Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE)…